Hot API Irbinitinib CAS:937263-43-9
Tukysa (Tucatinib)/Tucatinib (ONT-380) is an oral TKI(tyrosine kinase) inhibitor that is highly specific for HER2. On April 17, 2020, the FDA approved Tukysa in combination with trastuzumab and capecitabine. For the treatment of adults with surgically unresectable or metastatic advanced HER2-positive breast cancer.
Overview
Hot API Irbinitinib CAS:937263-43-9 is a new targeted anti-cancer drug jointly developed by Johnson and Pharmacyclics, and was approved by the U.S. Food and Drug Administration on November 13, 2013. This medicine is used to treat mantle cell lymphoma. MCL is a rare type of non-Hodgkin's lymphoma, which accounts for about 6% of people in the United States. MCL is usually diagnosed when cancer cells have spread to the bone marrow or other organs, which is a dangerous disease. Irbinitinib is a small molecule BTK inhibitor that binds to active substances in BTK, thereby inhibiting its activity. The full name of BTK is Bruton'styrosinekinase, which transmits signals in the BCR signaling pathway and the cytokine receptor signaling pathway. Preclinical studies have shown that ibrutinib can inhibit the proliferation and survival of malignant B cells.
Details
Name: Hot API Irbinitinib CAS:937263-43-9
EINECS:200-001-8
